All In MedTech

FDA Clearance Tracker · P180035-S004

MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 12, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P180035-S004
Device name
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
Applicant location
Pleasanton, CA
Received
Jan 15, 2020
Decided
Jul 12, 2021
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P180035

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code QIT

FDA's approval statement

As written in FDA's record.

Approval of the protocol for the MiSight®1 Day Safety Post Approval Study (PAS) protocol.

Source documents

Other decisions for CooperVision, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.